Search results
Results from the WOW.Com Content Network
Amgen (NASDAQ: AMGN) ... Financial metrics paint an encouraging picture. Amgen's generous 3.23% dividend yield essentially matches its peer group average of 3.28%. Moreover, the biotech's third ...
Amgen's financial results remain strong. In the third quarter, its revenue grew by 23% year over year to $8.5 billion. Even excluding its October 2023 acquisition of Horizon Therapeutics, Amgen's ...
Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large pharma company's stock to fall, especially considering that the market ...
Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months. Despite a string of solid earnings reports from the biotechnology giant ...
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. [3] [4] One of the world's largest independent biotechnology companies, As of 2022, Amgen has approximately 24,000 staff in total.
Richard D. Nanula was chief financial officer of Amgen Inc. and The Walt Disney Company, chief operating officer of Starwood, and chief executive officer of Broadband Sports. While a principal at Colony Capital, he resigned amid a sex scandal. He is currently the chief executive officer of Lucy Scientific Discovery Inc..
Amgen has increased its payouts by 201% in the past decade, and its forward yield is now around 3.7%. This is an excellent dividend growth stock to buy and hold. Don’t miss this second chance at ...
Bradway joined Amgen in 2006 as vice president of operations strategy, and was executive vice president and chief financial officer from April 2007 to May 2010. [6] He was its president and chief operating officer from May 2010 to May 2012. [7] In October 2011, he was appointed to the Amgen board of directors.